In silico binding free energy predictability by using the linear interaction energy (LIE) method: bromobenzimidazole

A Bortolato1, S Moro

  • 1Molecular Modeling Section, Department of Pharmaceutical Sciences, University of Padova, via Marzolo 5, I-35131 Padova, Italy.

Insights

This study used the Linear Interaction Energy (LIE) method to develop computational models for predicting the binding affinity of bromobenzimidazole inhibitors targeting Protein Kinase CK2 (CK2). The models efficiently rationalize inhibitor activity and binding modes.

Area of Science:

  • Biochemistry
  • Computational Chemistry
  • Drug Discovery

Background:

  • Protein kinase CK2 (CK2) is crucial for cell viability and implicated in tumor development and viral replication.
  • CK2 inhibitors represent potential therapeutic agents for cancer and viral infections.

Purpose of the Study:

  • To apply the Linear Interaction Energy (LIE) method with the Surface Generalized Born (SGB) solvation model to study bromobenzimidazole CK2 inhibitors.
  • To develop and validate computational models for predicting binding free energy (DeltaGbind) of these inhibitors.

Main Methods:

  • Utilized the LIE method and SGB continuum solvation model for binding free energy calculations.
  • Developed two models, "CK2scoreA" and "CK2scoreB", using a training set of 22 inhibitors.
  • Employed a stepwise approach to select tautomeric forms and binding positions.

Main Results:

  • Both developed models demonstrated statistical acceptability.
  • The best model achieved a correlation coefficient (r2) of 0.81 and predictive accuracy of 0.65 kcal/mol.
  • External validation with 16 analogs yielded a cross-validated correlation coefficient (q2) of 0.68 and RMSE of 0.78 kcal/mol.

Conclusions:

  • The LIE approach is an efficient methodology for understanding the activity differences of bromobenzimidazole CK2 inhibitors.
  • The study successfully rationalized key interactions and potential binding modes for this class of inhibitors.
  • Computational modeling provides valuable insights for the rational design of novel CK2-targeting drugs.

Related Concept Videos

The Equilibrium Binding Constant and Binding Strength02:18

The Equilibrium Binding Constant and Binding Strength

The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
The Equilibrium Binding Constant and Binding Strength02:18

The Equilibrium Binding Constant and Binding Strength

The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
Conserved Binding Sites01:49

Conserved Binding Sites

Many proteins’ biological role depends on their interactions with their ligands, small molecules that bind to specific locations on the protein known as ligand-binding sites. Ligand-binding sites are often conserved among homologous proteins as these sites are critical for protein function.
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally analyses the...
Ligand Binding Sites02:40

Ligand Binding Sites

Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-protein Interfaces02:04

Protein-protein Interfaces

Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a polypeptide...
Protein-Drug Binding: Mechanism and Kinetics01:16

Protein-Drug Binding: Mechanism and Kinetics

Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...